Evidence map›Paper›PMID 34372570›Full record

ArticleViruses2021

Neutralizing Antibodies in COVID-19 Patients and Vaccine Recipients after Two Doses of BNT162b2.

Julien Favresse, Constant Gillot, Laura Di Chiaro, Christine Eucher, Marc Elsen, Sandrine Van Eeckhoudt, Clara David, Laure Morimont, Jean-Michel Dogné, Jonathan Douxfils

Open access · goldAbstract read
In one paragraph

Article in Viruses, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed, 2 pooled it
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 2 syntheses or guidelines pooled it, 93 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Observational
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Sex-specific disparities in COVID-19 outcomes.Journal of the American College of Emergency Physicians open · 2024
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Transplacental transfer of anti-SARS-CoV-2 neutralizing antibodies in comparison to other pathogens total antibodies.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2023
    Article
  19. Article
  20. Article

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Julien FavresseDepartment of Laboratory Medicine, Clinique St-Luc Bouge, 5004 Namur, Belgium.
Constant GillotDepartment of Pharmacy, Namur Research Institute for Life Sciences, University of Namur, 5000 Namur, Belgium.ORCID 0000-0002-4151-9760
Laura Di ChiaroDepartment of Laboratory Medicine, Clinique St-Luc Bouge, 5004 Namur, Belgium.
Christine EucherDepartment of Laboratory Medicine, Clinique St-Luc Bouge, 5004 Namur, Belgium.
Marc ElsenDepartment of Laboratory Medicine, Clinique St-Luc Bouge, 5004 Namur, Belgium.
Sandrine Van EeckhoudtDepartment of Internal Medicine, Clinique St-Luc Bouge, 5004 Namur, Belgium.
Clara DavidQualiblood s.a., 5000 Namur, Belgium.
Laure MorimontQualiblood s.a., 5000 Namur, Belgium.
Jean-Michel DognéDepartment of Pharmacy, Namur Research Institute for Life Sciences, University of Namur, 5000 Namur, Belgium.
Jonathan DouxfilsDepartment of Pharmacy, Namur Research Institute for Life Sciences, University of Namur, 5000 Namur, Belgium.ORCID 0000-0002-7644-5298
Clinique Saint-Joseph · BEUniversity of Namur · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The evaluation of the neutralizing capacity of anti-SARS-CoV-2 antibodies is important because they represent real protective immunity. In this study we aimed to measure and compare the neutralizing antibodies (NAbs) in COVID-19 patients and in vaccinated individuals. One-hundred and fifty long-term samples from 75 COVID-19 patients were analyzed with a surrogate virus neutralization test (sVNT) and compared to six different SARS-CoV-2 serology assays. The agreement between the sVNT and pseudovirus VNT (pVNT) results was found to be excellent (i.e., 97.2%). The NAb response was also assessed in 90 individuals who had received the complete dose regimen of BNT162b2. In COVID-19 patients, a stronger response was observed in moderate-severe versus mild patients (

Indexed as

AdultAgedAged, 80 and overAntibodies, NeutralizingAntibodies, ViralBNT162 VaccineCOVID-19COVID-19 Serological TestingCOVID-19 VaccinesFemaleHumansMaleMiddle AgedNeutralization TestsSARS-CoV-2Serologic TestsAntibodies, NeutralizingAntibodies, ViralBNT162 VaccineCOVID-19 VaccinesCOVID-19humoral responselong-term kineticsneutralizing antibodiesSARS-CoV-2

Identifiers

PMID34372570
PMCPMC8309994
OpenAlexW3179119084

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.